Differential effects of benfluorex and two fibrate derivatives on serum lipoprotein patterns in hypertriglyceridemic type 2 diabetic patients

D. Sommariva, A. Branchi, M. Tirrito

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Twenty-eight hypertriglyceridemic type 2 diabetic patients were assigned to three different hypolipidemic treatment groups. Twelve were treated with benfluorex 150 mg TID, nine with fenofibrate 100 mg TID, and seven with bezafibrate 200 mg TID. After one month, serum triglyceride (TG) fell by 33%, serum cholesterol (Chol) by 17%, very low-density lipoprotein (VLDL)-TG by 36%, and low-density lipoprotein (LDL)-Chol by 20% in benfluorex-treated patients. High-density lipoprotein (HDL)-Chol did not change significantly. A significant decrease in glycosylated hemoglobin also occurred. In fenofibrate-treated patients serum TG decreased by 50% and VLDL-TG by 60%. LDL-Chol increased by 22% and HDL-Chol by 16%. Similar results were obtained in the bezafibrate group, eg, a significant decrease in serum TG (44%) and VLDL-TG (54%) and an increase in LDL-Chol (16%) and in HDL-Chol (21%) serum levels. Although the rise in LDL-Chol after administration of the two fibrates was associated with an increase in HDL-Chol, LDL-Chol to HDL-Chol ratio did not change in the fenofibrate and bezafibrate groups, but significantly decreased in benfluorex-treated patients. This may be of major importance in the development of atherosclerotic vascular lesions in diabetic patients.

Original languageEnglish
Pages (from-to)859-870
Number of pages12
JournalCurrent Therapeutic Research
Volume40
Issue number5
Publication statusPublished - 1986

Fingerprint

benfluorex
Fibric Acids
LDL Cholesterol
HDL Cholesterol
Lipoproteins
Bezafibrate
Fenofibrate
Serum
Triglycerides
Glycosylated Hemoglobin A
Blood Vessels
Cholesterol

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{0b4f71a5a86148bdba12417e9438beee,
title = "Differential effects of benfluorex and two fibrate derivatives on serum lipoprotein patterns in hypertriglyceridemic type 2 diabetic patients",
abstract = "Twenty-eight hypertriglyceridemic type 2 diabetic patients were assigned to three different hypolipidemic treatment groups. Twelve were treated with benfluorex 150 mg TID, nine with fenofibrate 100 mg TID, and seven with bezafibrate 200 mg TID. After one month, serum triglyceride (TG) fell by 33{\%}, serum cholesterol (Chol) by 17{\%}, very low-density lipoprotein (VLDL)-TG by 36{\%}, and low-density lipoprotein (LDL)-Chol by 20{\%} in benfluorex-treated patients. High-density lipoprotein (HDL)-Chol did not change significantly. A significant decrease in glycosylated hemoglobin also occurred. In fenofibrate-treated patients serum TG decreased by 50{\%} and VLDL-TG by 60{\%}. LDL-Chol increased by 22{\%} and HDL-Chol by 16{\%}. Similar results were obtained in the bezafibrate group, eg, a significant decrease in serum TG (44{\%}) and VLDL-TG (54{\%}) and an increase in LDL-Chol (16{\%}) and in HDL-Chol (21{\%}) serum levels. Although the rise in LDL-Chol after administration of the two fibrates was associated with an increase in HDL-Chol, LDL-Chol to HDL-Chol ratio did not change in the fenofibrate and bezafibrate groups, but significantly decreased in benfluorex-treated patients. This may be of major importance in the development of atherosclerotic vascular lesions in diabetic patients.",
author = "D. Sommariva and A. Branchi and M. Tirrito",
year = "1986",
language = "English",
volume = "40",
pages = "859--870",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Differential effects of benfluorex and two fibrate derivatives on serum lipoprotein patterns in hypertriglyceridemic type 2 diabetic patients

AU - Sommariva, D.

AU - Branchi, A.

AU - Tirrito, M.

PY - 1986

Y1 - 1986

N2 - Twenty-eight hypertriglyceridemic type 2 diabetic patients were assigned to three different hypolipidemic treatment groups. Twelve were treated with benfluorex 150 mg TID, nine with fenofibrate 100 mg TID, and seven with bezafibrate 200 mg TID. After one month, serum triglyceride (TG) fell by 33%, serum cholesterol (Chol) by 17%, very low-density lipoprotein (VLDL)-TG by 36%, and low-density lipoprotein (LDL)-Chol by 20% in benfluorex-treated patients. High-density lipoprotein (HDL)-Chol did not change significantly. A significant decrease in glycosylated hemoglobin also occurred. In fenofibrate-treated patients serum TG decreased by 50% and VLDL-TG by 60%. LDL-Chol increased by 22% and HDL-Chol by 16%. Similar results were obtained in the bezafibrate group, eg, a significant decrease in serum TG (44%) and VLDL-TG (54%) and an increase in LDL-Chol (16%) and in HDL-Chol (21%) serum levels. Although the rise in LDL-Chol after administration of the two fibrates was associated with an increase in HDL-Chol, LDL-Chol to HDL-Chol ratio did not change in the fenofibrate and bezafibrate groups, but significantly decreased in benfluorex-treated patients. This may be of major importance in the development of atherosclerotic vascular lesions in diabetic patients.

AB - Twenty-eight hypertriglyceridemic type 2 diabetic patients were assigned to three different hypolipidemic treatment groups. Twelve were treated with benfluorex 150 mg TID, nine with fenofibrate 100 mg TID, and seven with bezafibrate 200 mg TID. After one month, serum triglyceride (TG) fell by 33%, serum cholesterol (Chol) by 17%, very low-density lipoprotein (VLDL)-TG by 36%, and low-density lipoprotein (LDL)-Chol by 20% in benfluorex-treated patients. High-density lipoprotein (HDL)-Chol did not change significantly. A significant decrease in glycosylated hemoglobin also occurred. In fenofibrate-treated patients serum TG decreased by 50% and VLDL-TG by 60%. LDL-Chol increased by 22% and HDL-Chol by 16%. Similar results were obtained in the bezafibrate group, eg, a significant decrease in serum TG (44%) and VLDL-TG (54%) and an increase in LDL-Chol (16%) and in HDL-Chol (21%) serum levels. Although the rise in LDL-Chol after administration of the two fibrates was associated with an increase in HDL-Chol, LDL-Chol to HDL-Chol ratio did not change in the fenofibrate and bezafibrate groups, but significantly decreased in benfluorex-treated patients. This may be of major importance in the development of atherosclerotic vascular lesions in diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=0022978513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022978513&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 859

EP - 870

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -